IRB #

STUDY00015752

Title

A Phase 1/2, Open-Label Safety and Efficacy Evaluation of CRS-207 in Combination with Epacadostat in Adults with Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer

Principal Investigator

Matthew Taylor

Study Purpose

The study is being done to test any good and bad effects of CRS-207 in combination with epacadostat and pembrolizumab in women with platinum-resistant ovarian, fallopian or peritoneal cancer.

Medical Condition(s)

Ovarian cancer
Fallopian cancer
Peritoneal cancer

Eligibility Criteria

1. Women 18 years or older
2. Platinum-resistant ovarian, fallopian or peritoneal cancer
3. Adequate organ function
4. Other criteria apply

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Participants will receive the study drug(s) as long as their cancer does not get worse and they do not develop side effects that they cannot tolerate. Participants who stop taking study drug due to reasons other than worsening disease will be contacted and have their disease assessed every 9 weeks until the start of a new anticancer treatment, documented worsening disease or until the end of the study. If a participant stops treatment due to worsening disease, participants will be contacted by phone every 12 weeks after last dose of study drug(s) until the end of the study.

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080

Sponsor

Aduro Biotech, Inc

Recruitment End

12/31/2022

Compensation Provided

No


Go Back